 Hyperphosphatemia
"Hyperphosphatemia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum.
| Descriptor ID |
D054559
|
| MeSH Number(s) |
C18.452.750.199
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hyperphosphatemia".
Below are MeSH descriptors whose meaning is more specific than "Hyperphosphatemia".
This graph shows the total number of publications written about "Hyperphosphatemia" by people in this website by year, and whether "Hyperphosphatemia" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 | | 2010 | 0 | 2 | 2 | | 2012 | 1 | 0 | 1 | | 2014 | 1 | 0 | 1 | | 2016 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2020 | 1 | 0 | 1 | | 2022 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Hyperphosphatemia" by people in Profiles.
-
Perez L, You Z, Teitelbaum I, Andrews ES, Reddin R, Ramirez-Renteria L, Wilson G, Kendrick J. A 6-Month clinical practice pilot study of sucroferric oxyhydroxide on nutritional status in patients on peritoneal dialysis. BMC Nephrol. 2022 07 09; 23(1):245.
-
Miyazaki-Anzai S, Keenan AL, Blaine J, Miyazaki M. Targeted Disruption of a Proximal Tubule-Specific TMEM174 Gene in Mice Causes Hyperphosphatemia and Vascular Calcification. J Am Soc Nephrol. 2022 08; 33(8):1477-1486.
-
Ginsberg C, Zelnick LR, Block GA, Chertow GM, Chonchol M, Hoofnagle A, Kestenbaum B, de Boer IH. Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease. Nephrol Dial Transplant. 2020 04 01; 35(4):616-623.
-
Kendrick J, Parameswaran V, Ficociello LH, Ofsthun NJ, Davis S, Mullon C, Kossmann RJ, Kalantar-Zadeh K. One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis. J Ren Nutr. 2019 09; 29(5):428-437.
-
Rascati K. Comment on: "Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Mode". Drugs R D. 2017 09; 17(3):487-488.
-
Marcuccilli M, Chonchol M, Jovanovich A. Phosphate Binders and Targets Over Decades: Do We have it Right Now? Semin Dial. 2017 03; 30(2):134-141.
-
Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, Lim WT, LoRusso P, Shapiro GI, Parker K, Chen X, Choudhury S, Ringeisen F, Graus-Porta D, Porter D, Isaacs R, Buettner R, Wolf J. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. J Clin Oncol. 2017 Jan 10; 35(2):157-165.
-
Cozzolino M, Funk F, Rakov V, Phan O, Teitelbaum I. Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide. Curr Drug Metab. 2014; 15(10):953-65.
-
W?thrich RP, Chonchol M, Covic A, Gaillard S, Chong E, Tumlin JA. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol. 2013 Feb; 8(2):280-9.
-
Kido S, Nomura K, Sasaki S, Shiozaki Y, Segawa H, Tatsumi S. [Information about phosphorus additives and nutritional counseling]. Clin Calcium. 2012 Oct; 22(10):1583-91.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|